Imatinib, for example, which has led to a significant increase in CML survival rates by selectively targeting the tumor-specific protein BCR/ABL, was included for the treatment of gastrointestinal stromal tumors (GIST), which are characterized by KIT-activating mutations [953]. The gene discussed is BCR; the disease is gastrointestinal stromal tumor.